| Literature DB >> 34692826 |
Ali Asghari1, Hamidreza Majidiani2, Taher Nemati3, Mohammad Fatollahzadeh3, Morteza Shams2, Razi Naserifar2, Bahareh Kordi4.
Abstract
Toxoplasmosis is a global threat with significant zoonotic concern. The present in silico study was aimed at determination of bioinformatics features and immunogenic epitopes of a tyrosine-rich oocyst wall protein (TrOWP) of Toxoplasma gondii. After retrieving the amino acid sequence from UniProt database, several parameters were predicted including antigenicity, allergenicity, solubility and physico-chemical features, signal peptide, transmembrane domain, and posttranslational modifications. Following secondary and tertiary structure prediction, the 3D model was refined, and immunogenic epitopes were forecasted. It was a 25.57 kDa hydrophilic molecule with 236 residues, a signal peptide, and significant antigenicity scores. Moreover, several linear and conformational B-cell epitopes were present. Also, potential mouse and human cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes were predicted in the sequence. The findings of the present in silico study are promising as they render beneficial characteristics of TrOWP to be included in future vaccination experiments.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34692826 PMCID: PMC8531782 DOI: 10.1155/2021/1315618
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Secondary structure prediction for TrOWP using GOR IV web server. (a) Sequence-based prediction results indicated that 54.24%, 33.05%, and 12.71% of the sequence are dedicated to the random coil (yellow C), alpha helix (blue H), and extended strand (red E), respectively. (b) Graphical illustration of the secondary structure by GOR IV server.
Figure 2Graphical illustration of secondary structure prediction of TrOWP using PSIPRED server.
Figure 3Protein 3D modelling and validation. (a) The final tertiary model of the TrOWP gathered following homology modelling by I-TASSER web server, as shown in ribbon and surface. (b) Ramachandran plot analysis of the initial model showed 74.33%, 16.57%, and 9.09% of the residues in favored, allowed, and outlier areas, respectively. (c) After refinement, 88.77%, 8.56%, and 2.67% of the residues are in favored, allowed, and outlier regions, respectively.
The final screening of shared linear B-cell epitopes from T. gondii tyrosine-rich oocyst wall protein.
| B-cell epitopes | Antigenicity | Allergenicity | Solubility |
|---|---|---|---|
| YPGYGYGYPGYGYG | 0.2095 | No | Poor |
| EEAAEPDE | 0.7107 | No | Good |
| VAASSNLTPDNA | 0.5596 | Yes | Poor |
| EPDEDKKDDS | 1.4261 | No | Good |
| QGNDEHSSQ | 1.7231 | No | Good |
| TNNEDEQ | 1.8297 | No | Good |
| AGAPQNEVAAT | 1.1823 | No | Good |
| PRLSGRQRLLGL | 0.2650 | No | Good |
| SQKLSFIECDCRK | 0.8220 | No | Good |
Specific B-cell linear epitopes of T. gondii tyrosine-rich oocyst wall protein based on different physico-chemical parameters predicted by the Bcepred web server.
| Physico-chemical parameter | B-cell epitopes |
|---|---|
| Hydrophilicity | VAQETEEAKLTSDSEKVA, AGAPQNE, ECDCRKKR, PRQESEGSTMK |
| Flexibility | EEAKLTSDSE, EKLTDEKGSG, IECDCRKKRVRG, GFFPRQESEGSTMKPRLSGRQ |
| Accessibility | TRTVAQETEEAKLTSDSEKV, SNLTPDN, ECDCRKKRVRGTG, KEAFRHS, FFPRQESEGSTMKPRLSGRQR |
| Turns | EATNNEDE, GNDEHSSQ |
| Exposed surface | QETEEAK, EKLTDEK, ECDCRKKRVRGT |
| Polarity | VAQETEEAKLTS, IECDCRKKRVRGTG, VKEAFRHSL, FPRQESEGS, KPRLSGRQR |
| Antigenic propensity | GFIKILLLLGLL, KLSFIECDCR, FRHSLLPWFLP |
Figure 4Predicted conformational B-cell epitopes of TrOWP by ElliPro tool of IEDB analysis resource. Length and score of each protein are provided.
Mouse specific MHC-I epitopes predicted by CTLpred server with subsequent screening for immunogenicity, allergenicity, and hydrophobicity.
| Mouse MHC-I alleles | T-cell peptide | Immunogenicity score | Allergenicity | Hydrophobicity (%) |
|---|---|---|---|---|
| H2-Db (MHC-I) | AASSNLTPDNAL | -0.17199 | Yes | 50 |
| ALAGAPQNEVAA | 0.10695 | No | 66.67 | |
| FFPRQESEGSTM | -0.11546 | No | 33.33 | |
| H2-Dd (MHC-I) | FGGFGPGFGVGF | 0.38454 | No | 50 |
| KGFIKILLLLGL | 0.06992 | Yes | 66.67 | |
| RHSLLPWFLPGF | 0.24324 | No | 66.67 | |
| H2-Kb (MHC-I) | KGFIKILLLLGL | 0.06992 | Yes | 66.67 |
| RHSLLPWFLPGF | 0.24324 | No | 66.67 | |
| FGGFGPGFGVGF | 0.38454 | No | 50 | |
| H2-Kd (MHC-I) | FFPRQESEGSTM | -0.11546 | No | 33.33 |
| GYPGYGYPGYGF | 0.09408 | No | 25 | |
| GFGPGFGVGFTF | 0.37342 | No | 50 | |
| H2-Kk (MHC-I) | QESEGSTMKPRL | -0.39637 | Yes | 25 |
| EEAKLTSDSEKV | -0.51403 | Yes | 25 | |
| DLVKEAFRHSLL | -0.01925 | Yes | 50 | |
| H2-Ld (MHC-I) | HSLLPWFLPGFF | 0.3799 | No | 75 |
| YPGYGYGYGYGY | 0.11446 | No | 8.33 | |
| EAFRHSLLPWFL | 0.18378 | No | 66.67 |
Mouse specific MHC-II epitopes predicted by IEDB server with subsequent screening for antigenicity and allergenicity as well as IFN-γ and IL-4 induction.
| Mouse MHC-II alleles | T-cell peptide | Antigenicity | Allergenicity | IFN- | IL-4 induction | ||
|---|---|---|---|---|---|---|---|
| Result | Score | Result | Score | ||||
| H2-IAb (MHC-II) | PDNALAGAPQNEVAA | 1.2048 | Yes | Negative | -0.6321 | Negative | -1.02 |
| TPDNALAGAPQNEVA | 0.9905 | No | Negative | -0.6006 | Negative | -1.01 | |
| RKKRVRGTGAPCSCA | 2.1439 | No | Negative | -0.249 | Positive | 0.39 | |
| H2-IAd (MHC-II) | IKILLLLGLLAVTTR | 0.6131 | No | Negative | 4 | Negative | -0.75 |
| LTSDSEKVAASSNLT | 1.2417 | Yes | Negative | 2 | Negative | -0.38 | |
| SDSEKVAASSNLTPD | 1.0754 | No | Negative | 2 | Negative | -0.41 | |
| H2-IEd (MHC-II) | SFIECDCRKKRVRGT | 1.8125 | No | Negative | -0.3691 | Positive | 0.29 |
| CDCRKKRVRGTGAPC | 1.7682 | No | Positive | 1 | Positive | 0.29 | |
| ADLVKEAFRHSLLPW | 0.7519 | Yes | Positive | 1 | Positive | 0.23 | |
Human specific MHC-I epitopes predicted by CTLpred server with subsequent screening for immunogenicity, allergenicity, and hydrophobicity.
| Human MHC class I supertype | CTL epitopes | Immunogenicity score | Allergenicity | Hydrophobicity (%) |
|---|---|---|---|---|
| A1 supertype | GLGNLFGGY | 0.15229 | No | 33.33 |
| CADLVKEAF | -0.0594 | No | 55.56 | |
| ATEKLTDEK | -0.08154 | Yes | 22.22 | |
| A2 supertype | LLLLGLLAV | 0.0213 | No | 88.89 |
| KLTSDSEKV | -0.3295 | Yes | 22.22 | |
| LLAVTTRTV | 0.19494 | Yes | 55.56 | |
| GLLAVTTRT | 0.17551 | No | 44.44 | |
| FLPGFFPRQ | 0.27558 | No | 66.67 | |
| A3 supertype | TMKPRLSGR | -0.16102 | No | 33.33 |
| GLGNLFGGY | 0.15229 | No | 33.33 | |
| A24 supertype | GYGYPGYGF | 0.04506 | No | 22.22 |
| GFIKILLLL | -0.07048 | No | 77.78 | |
| YYPGYGYGY | 0.07548 | No | 11.11 | |
| RLLGLGNLF | 0.03966 | Yes | 55.56 | |
| RHSLLPWFL | 0.16924 | No | 66.67 | |
| B7 supertype | YPGYGFGGF | 0.19888 | No | 33.33 |
| LPWFLPGFF | 0.26546 | No | 88.89 | |
| KPRLSGRQR | -0.14756 | No | 22.22 | |
| RVRGTGAPC | 0.14714 | Yes | 33.33 | |
| APQNEVAAT | 0.14813 | No | 55.56 | |
| APCSCADLV | -0.1874 | No | 55.56 | |
| SGRQRLLGL | -0.04936 | No | 33.33 |
Human specific MHC-II epitopes predicted by IEDB server using HLA reference set with subsequent screening for antigenicity and allergenicity as well as IFN-γ and IL-4 induction.
| Human MHC-II allele | HTL epitope | Method | Percentile rank | Antigenicity | Allergenicity | IFN- | IL-4 induction | ||
|---|---|---|---|---|---|---|---|---|---|
| Result | Score | Result | Score | ||||||
| HLA-DRB1∗01 : 01 | FIKILLLLGLLAVTT | Consensus (comb.lib./smm/nn) | 0.10 | 0.8754 | No | Negative | 61 | Negative | -0.74 |
| HLA-DRB1∗15 : 01 | FIKILLLLGLLAVTT | Consensus (smm/nn/sturniolo) | 0.93 | 0.8754 | No | Negative | 61 | Negative | -0.74 |
| HLA-DPA1∗01 : 03/DPB1∗04 : 01 | LVKEAFRHSLLPWFL | NetMHCIIpan | 0.95 | 0.8487 | Yes | Negative | -0.0405 | Positive | 0.02 |
| HLA-DPA1∗02 : 01/DPB1∗05 : 01 | MKGFIKILLLLGLLA | Consensus (comb.lib./smm/nn) | 1.10 | 0.9498 | No | Negative | 71 | Negative | -0.74 |
| HLA-DPA1∗01 : 03/DPB1∗02 : 01 | HSLLPWFLPGFFPRQ | Consensus (comb.lib./smm/nn) | 1.40 | 1.2901 | No | Positive | 1 | Negative | 0.15 |
| HLA-DPA1∗01 : 03/DPB1∗04 : 01 | KEAFRHSLLPWFLPG | NetMHCIIpan | 1.50 | 0.7021 | Yes | Positive | 0.0844 | Negative | 0.07 |
| HLA-DPA1∗03 : 01/DPB1∗04 : 02 | GFIKILLLLGLLAVT | Consensus (comb.lib./smm/nn) | 1.60 | 0.4212 | No | Negative | 71 | Negative | -0.74 |
| HLA-DPA1∗01 : 03/DPB1∗04 : 01 | HSLLPWFLPGFFPRQ | NetMHCIIpan | 1.60 | 1.2901 | No | Positive | 1 | Negative | 0.15 |
| HLA-DPA1∗03 : 01/DPB1∗04 : 02 | MKGFIKILLLLGLLA | Consensus (comb.lib./smm/nn) | 1.60 | 0.9498 | No | Negative | 1 | Negative | -0.74 |
| HLA-DQA1∗01 : 01/DQB1∗05 : 01 | FRHSLLPWFLPGFFP | Consensus (comb.lib./smm/nn) | 1.90 | 1.5483 | No | Negative | -0.0952 | Negative | 0.14 |
| HLA-DPA1∗01 : 03/DPB1∗04 : 01 | EAFRHSLLPWFLPGF | NetMHCIIpan | 2.00 | 0.9177 | Yes | Negative | -0.0048 | Negative | 0.08 |
| HLA-DQA1∗01 : 01/DQB1∗05 : 01 | HSLLPWFLPGFFPRQ | Consensus (comb.lib./smm/nn) | 2.00 | 1.2901 | No | Positive | 1 | Negative | 0.15 |
| HLA-DPA1∗02 : 01/DPB1∗01 : 01 | RHSLLPWFLPGFFPR | Consensus (comb.lib./smm/nn) | 2.30 | 1.1923 | No | Positive | 0.0806 | Negative | 0.15 |
| HLA-DRB1∗03 : 01 | KLSFIECDCRKKRVR | Consensus (smm/nn/sturniolo) | 2.40 | 1.1250 | No | Negative | -0.3371 | Positive | 0.29 |